Literature DB >> 15928583

Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-alpha.

Richard E Kast1, Erick L Altschuler.   

Abstract

Crohn's disease and B cell chronic lymphocytic leukemia (CLL) share a common link in their pathologic mechanisms. Lymphocytes in both diseases fail to undergo apoptosis and die properly. That failure is partly due to increased signaling by tumor necrosis factor (TNF)-alpha, and their respective pathologies directly follow from this apoptosis failure. Bupropion is a commonly used generic antidepressant in clinical use for over a decade, and early evidence indicates it lowers TNF levels. This paper suggests the use of bupropion in CLL to lower TNF levels, which may thereby slow CLL disease course.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15928583

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  9 in total

1.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

Review 2.  Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications.

Authors:  R E Kast
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  The antidepressant bupropion exerts alleviating properties in an ovariectomized osteoporotic rat model.

Authors:  Hatem M Abuohashish; Mohammed M Ahmed; Salim S Al-Rejaie; Kamal E H Eltahir
Journal:  Acta Pharmacol Sin       Date:  2014-12-29       Impact factor: 6.150

Review 4.  Inflammation and survival pathways: chronic lymphocytic leukemia as a model system.

Authors:  Lisa S Chen; Kumudha Balakrishnan; Varsha Gandhi
Journal:  Biochem Pharmacol       Date:  2010-08-07       Impact factor: 5.858

5.  PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.

Authors:  Dalia El-Gamal; Katie Williams; Taylor D LaFollette; Matthew Cannon; James S Blachly; Yiming Zhong; Jennifer A Woyach; Erich Williams; Farrukh T Awan; Jeffrey Jones; Leslie Andritsos; Kami Maddocks; Chia-Hsien Wu; Ching-Shih Chen; Amy Lehman; Xiaoli Zhang; Rosa Lapalombella; John C Byrd
Journal:  Blood       Date:  2014-07-07       Impact factor: 22.113

6.  Antidepressants and inflammatory bowel disease: a systematic review.

Authors:  Antonina A Mikocka-Walus; Deborah A Turnbull; Nicole T Moulding; Ian G Wilson; Jane M Andrews; Gerald J Holtmann
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-09-20

7.  Graph theoretic network analysis reveals protein pathways underlying cell death following neurotropic viral infection.

Authors:  Sourish Ghosh; G Vinodh Kumar; Anirban Basu; Arpan Banerjee
Journal:  Sci Rep       Date:  2015-09-25       Impact factor: 4.379

8.  Synthesis, screening and pharmacokinetic evaluation of potential prodrugs of bupropion. Part one: in vitro development.

Authors:  Paul Matthew O'Byrne; Robert Williams; John J Walsh; John F Gilmer
Journal:  Pharmaceuticals (Basel)       Date:  2014-05-14

9.  Part Two: Evaluation of N-methylbupropion as a Potential Bupropion Prodrug.

Authors:  Paul Matthew O'Byrne; Robert Williams; John J Walsh; John F Gilmer
Journal:  Pharmaceuticals (Basel)       Date:  2014-05-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.